INS and Insulin resistance: Therefore, chronic sitagliptin treatment has promoted a reduction of glucose and HbA1c levels, together with a partial correction of insulin reduction and an improvement of insulin resistance (HOMA-IR), which is in agreement with other reports [37, 38].